William has made over 2 trades of the AIM ImmunoTech Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 9,677 units of AIM stock worth 38,998$ on 21 June 2019.
The largest trade he's ever made was buying 9,677 units of AIM ImmunoTech Inc stock on 21 June 2019 worth over 38,998$. On average, William trades about 207 units every 79 days since 2004. As of 21 June 2019 he still owns at least 20,838 units of AIM ImmunoTech Inc stock.
You can see the complete history of William Mitchell stock trades at the bottom of the page.
Dr. William M. Mitchell, M.D., Ph.D., is Chairman of the Board of the Company. He was appointed Chairman of the Board in February 2016 after serving as a Director since July 1998. Dr. Mitchell is a Professor of Pathology, Microbiology & Immunology at Vanderbilt University School of Medicine and is a board certified physician. Dr. Mitchell earned a M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as House Officer in Internal Medicine (Osler Service), followed by a Fellowship at its School of Medicine. Dr. Mitchell has published over 200 papers, reviews and abstracts that relate to the pathogenesis of obligate intracellular pathogens, innate and adaptive immune responses, and liquid biopsy cancer (chromosomal instability) diagnostics. He is the inventor or co-inventor of 14 issued US patents as well as derivative foreign patents. Dr. Mitchell has worked with many professional societies that have included the American Society of Investigative Pathology (ASIP), the International Society for Antiviral Research (ISAR), the American Society of Biochemistry and Molecular Biology (ASBMB), the American Society of Microbiology (ASM), and the American Society of Clinical Oncology (ASCO). Dr. Mitchell is a member of the American Medical Association (AMA). He has served on numerous review committees for the National Institutes of Health (NIH), the Centers for Disease Control (CDC), the European Union (EU), and the College of American Pathology (CAP). He is an independent director of Chronix Biomedical, a genetics based cancer diagnostic company.
As the Chairman of the Board of AIM ImmunoTech Inc, the total compensation of William Mitchell at AIM ImmunoTech Inc is 1,696,680$. There are no executives at AIM ImmunoTech Inc getting paid more.
William Mitchell is 81, he's been the Chairman of the Board of AIM ImmunoTech Inc since 2016. There are no older and 14 younger executives at AIM ImmunoTech Inc.
William's mailing address filed with the SEC is 2117 SW HWY 484, , OCALA,, FL, 34473.
Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over 15,026,013$ worth of AIM ImmunoTech Inc stock and bought 898,126 units worth 656,210$ . The most active insiders traders include Thomas K Equels、J Mervyn Nabors、Commercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of 16,943$. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth 25,309$.
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
AIM ImmunoTech Inc executives and other stock owners filed with the SEC include: